Singapore: Japan-based Daiichi Sankyo has launched antihypertensive franchise olmesartan medoxomil in Mexico under the name Openvas. It has also launched Openvas Co, a combination preparation for use with a diuretic.

Daiichi Sankyo Mexico was established in 2011 to leverage the Group's Hybrid Business Model in Mexico to offer both innovative and established medicines in Latin America's second largest market. Openvas and Openvas Co are the first innovative pharmaceuticals marketed in Mexico by a Daiichi Sankyo Group company.

Through the marketing of both agents, Daiichi Sankyo Mexico will contribute to treatment of hypertension in Mexico.